Gupta, Anu

Introduction: Although alterations in mitochondrial function have been observed in senescent hearts, the molecular basis for aging-associated decline in energy metabolism in the human heart is not fully understood. Objective: To determine aging-related changes in functional activity and protein expression level of mitochondrial oxidative phosphorylation (OXPHOS) complexes and expression of genes regulating mitochondrial energetics in the human heart. Methods: Right atrial appendages from well-matched adult (29-57 y.o., n=19) and aged (65-85 y.o., n=22) patients undergoing elective CABG surgery were used. Functional activity of OXPHOS complexes was measured spectrophotometrically. Protein expression level of corresponding OXPHOS protein subunits was determined by Western blot. Gene expression profiling was performed using Affymetrix Human Genome U133 Plus 2.0 microarrays. Results: Mitochondria from senescent hearts demonstrated a significant decrease in complex I and V functional activity without significant changes in the rest of the complexes (Fig. A). At the protein expression level, there was reduction in complex I, III, and IV (Fig. B). This was associated with downregulation of the majority (86%, 90 of 105) of genes coding mitochondrial proteins (Fig. C). Forty-six percent (41 of 90) of the downregulated genes were confined to pathways regulating mitochondrial energetics. Conclusion: With aging, the functional activity of OXPHOS is reduced due to supression of protein expression and downregulation of genes regulating mitochondrial energetics. This provides a substrate for reduced energetic efficiency associated with senescence in the human atria.

Next-generation screening of disease-related metabolomic phenotypes requires monitoring of both metabolite levels and turnover rates. Stable isotope18O-assisted31P nuclear magnetic resonance (NMR) and mass spectrometry uniquely allows simultaneous measurement of phosphometabolite levels and turnover rates in tissue and blood samples. The18O labeling procedure is based on the incorporation of one18O into Pifrom [18O]H2O with each act of ATP hydrolysis and the distribution of18O-labeled phosphoryls among phosphate-carrying molecules. This enables simultaneous recording of ATP synthesis and utilization, phosphotransfer fluxes through adenylate kinase, creatine kinase, and glycolytic pathways, as well as mitochondrial substrate shuttle, urea and Krebs cycle activity, glycogen turnover, and intracellular energetic communication. Application of expanded18O-labeling procedures has revealed significant differences in the dynamics of G-6-P[18O] (glycolysis), G-3-P[18O] (substrate shuttle), and G-1-P[18O] (glycogenolysis) between human and rat atrial myocardium. In human atria, the turnover of G-3-P[18O], which defects are associated with the sudden death syndrome, was significantly higher indicating a greater importance of substrate shuttling to mitochondria. Phosphometabolomic profiling of transgenic hearts deficient in adenylate kinase (AK1−/−), which altered levels and mutations are associated to human diseases, revealed a stress-induced shift in metabolomic profile with increased CrP[18O] and decreased G-1-P[18O] metabolic dynamics. The metabolomic profile of creatine kinase M-CK/ScCKmit−/−-deficient hearts is characterized by a higher G-6-[18O]P turnover rate, G-6-P levels, glycolytic capacity, γ/β-phosphoryl of GTP[18O] turnover, as well as β-[18O]ATP and β-[18O]ADP turnover, indicating altered glycolytic, guanine nucleotide, and adenylate kinase metabolic flux. Thus,18O-assisted gas chromatography-mass spectrometry and31P NMR provide a suitable platform for dynamic phosphometabolomic profiling of the cellular energetic system enabling prediction and diagnosis of metabolic diseases states.